JOINT FILING AGREEMENTJoint Filing Agreement • August 10th, 2006 • CPMG Inc • Biological products, (no disgnostic substances)
Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including any amendment, supplement, and/or exhibit thereto) with the Securities and Exchange Commission (and, if such security is registered on a national securities exchange or national securities association, also with the exchange or association), and further agrees to the filing and/or incorporation by reference of this Joint Filing Agreement as an exhibit thereto. This Joint Filing Agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party.
Lock-up AgreementLock-Up Agreement • June 6th, 2016 • CPMG Inc • Pharmaceutical preparations
This letter is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) between Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Citigroup Global Markets Inc. and Cowen and Company, LLC (together, the “Representatives”) as representatives of a group of Underwriters named therein, relating to an underwritten public offering of Class A Common Stock, $0.001 par value per share (the “Common Stock”), of the Company (the “Offering”).
JOINT FILING AGREEMENT August 10, 2006Joint Filing Agreement • February 14th, 2007 • CPMG Inc • Biological products, (no disgnostic substances)
Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including any amendment, supplement, and/or exhibit thereto) with the Securities and Exchange Commission (and, if such security is registered on a national securities exchange or national securities association, also with the exchange or association), and further agrees to the filing and/or incorporation by reference of this Joint Filing Agreement as an exhibit thereto. This Joint Filing Agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party.
JOINT FILING AGREEMENTJoint Filing Agreement • June 6th, 2016 • CPMG Inc • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13D with respect to the Class A Common Stock of Reata Pharmaceuticals, Inc., dated as of June 6, 2016 is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.
JOINT FILING AGREEMENT August 10, 2006Joint Filing Agreement • August 10th, 2006 • CPMG Inc • Biological products, (no disgnostic substances)
Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including any amendment, supplement, and/or exhibit thereto) with the Securities and Exchange Commission (and, if such security is registered on a national securities exchange or national securities association, also with the exchange or association), and further agrees to the filing and/or incorporation by reference of this Joint Filing Agreement as an exhibit thereto. This Joint Filing Agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party.
BUYER AGREEMENT December 10, 2008Buyer Agreement • December 12th, 2008 • CPMG Inc • Biological products, (no disgnostic substances)
The undersigned (the “Buyer”) hereby represents, warrants, and certifies to each party identified as a “Seller” on Exhibit A hereto (each, a “Seller” and, collectively, the “Sellers”), in connection with the sale by each Seller to the Buyer, and the purchase by the Buyer from each Seller (each, a “Sale” and, collectively, the “Sales”), of the securities (the “Securities”) of the issuer (the “Issuer”) contemplated by Exhibit A hereto that, effective on and as of the date hereof and at and as of the time of each Sale, to the same extent and with the same effect as if made at and as of the time of each Sale:
JOINT FILING AGREEMENTJoint Filing Agreement • April 1st, 2021 • CPMG Inc • Biological products, (no disgnostic substances)
The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Instil Bio, Inc., dated as of April 1, 2021, is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.
Lock-up AgreementLock-Up Agreement • June 6th, 2016 • CPMG Inc • Pharmaceutical preparations
This letter is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) between Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Citigroup Global Markets Inc. and Cowen and Company, LLC (together, the “Representatives”) as representatives of a group of Underwriters named therein, relating to an underwritten public offering of Class A Common Stock, $0.001 par value per share (the “Common Stock”), of the Company (the “Offering”).
